288385-99-9

Basic information

• Product Name: 2-PROPANONE, 1-(2-FLUORO-3-METHOXY-6-NITROPHENYL)-
• Synonyms: 2-PROPANONE, 1-(2-FLUORO-3-METHOXY-6-NITROPHENYL)-
• CAS NO: 288385-99-9
• Molecular Formula: C₁₀H₁₀FNO₄
• Molecular Weight: 227.19
• Mol File: 288385-99-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 347.933°C at 760 mmHg
• Flash Point: 164.224°C
• Appearance: /
• Density: 1.291g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.522
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-PROPANONE, 1-(2-FLUORO-3-METHOXY-6-NITROPHENYL)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PROPANONE, 1-(2-FLUORO-3-METHOXY-6-NITROPHENYL)-(288385-99-9)
• EPA Substance Registry System: 2-PROPANONE, 1-(2-FLUORO-3-METHOXY-6-NITROPHENYL)-(288385-99-9)

Safety Data

• Hazardous Substances Data: 288385-99-9(Hazardous Substances Data)

Usage

General Description

2-Propanone, 1-(2-fluoro-3-methoxy-6-nitrophenyl)- is a chemical compound with the molecular formula C10H9FNO4. It is a derivative of 2-Propanone, also known as acetone, that contains a 2-fluoro-3-methoxy-6-nitrophenyl group. 2-Propanone, 1-(2-fluoro-3-methoxy-6-nitrophenyl)- is commonly used in the synthesis of pharmaceuticals and agrochemicals due to its ability to inhibit certain enzymes and biological pathways. It is also utilized as a building block in the production of various organic compounds. Additionally, it has been studied for potential applications in medicinal chemistry and drug development. The compound's structural and physicochemical properties make it a valuable tool in chemical research and product development.

InChI:InChI=1/C10H10FNO4/c1-6(13)5-7-8(12(14)15)3-4-9(16-2)10(7)11/h3-4H,5H2,1-2H3

Upstream product

• 288385-96-6 1,2-difluoro-3-(2,2-dimethoxypropyl)-4-nitrobenzene 
• 1022112-32-8 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoic acid ethyl ester 
• 67-56-1 methanol 
• 121247-16-3 1-(2,3-difluoro-6-nitrophenyl)propan-2-one 
• 771-69-7 2,3,4-trifluoronitrobenzene 

Downstream Products

• 649736-31-2 1-(2-fluoro-3-hydroxy-6-nitrophenyl)propan-2-one 
• 649736-29-8 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 
• 649735-41-1 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol 
• 288385-88-6 4-fluoro-2-methyl-1H-indol-5-ol 
• 952490-01-6 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yl pivalate 
• 288385-93-3 2-methyl-4-fluoro-5-methoxy-1H-indole 

Relevant articles and documents

NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF

The present invention provides a novel nucleoside phosphoramidate compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The present invention also provides the pharmaceutical composition comprising a compound of the present invention, or a stereoisomer, salt, hydrate, solvate or crystal thereof and a use of the compound or the composition of the present invention in the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The compound of the present invention has a good anti-HCV effect.

PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS

The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Cinnoline compounds

The invention relatest to compounds of the formula (I) wherein either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or a direct bond; Z is linked to any one of G1, G2, G3 and G4 which is a free carbon atom; n is an integer from 0 to 5; any of the substitutents R1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 3; Ra represents hydrogen; Rb represents hydrogen or another value as defined herein; R1 represents hydrogen, oxo, hydroxy, halogeno, C1-4alkyl, C1-4alkoxy, C1-4alkoxy, C1-4-alkyl, aminoC1-4alkyl, C1-3alkylaminoC1-4alkyl, di(C1-3alkyl)aminoC1-4alkyl, —C1-5alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinly, N-ethylpiperazinyl, morpholino and thiomorpholino; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3aklylsulphanyl, —NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1— (wherein R5 and X1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.